Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Ultragenyx Pharmaceutical Inc. price momentum is very positive. Ultragenyx Pharmaceutical Inc. is not very popular among insiders. Ultragenyx Pharmaceutical Inc. is a mediocre stock to choose.
Log in to see more information.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification,...
RARE Fundamental Data by TradingView

News

Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $87.43
Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $87.43

Zolmax Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have received a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the stock, MarketBeat.com...\n more…

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Brokerages
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Brokerages

Ticker Report Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, Marketbeat Ratings...\n more…

Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Adial Pharmaceuticals (NASDAQ:ADIL)
Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Adial Pharmaceuticals (NASDAQ:ADIL)

Zolmax Adial Pharmaceuticals (NASDAQ:ADIL - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) are both medical companies, but which is the superior business? We will contrast...\n more…

Pinnacle Associates Ltd. Buys 41,633 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Pinnacle Associates Ltd. Buys 41,633 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Ticker Report Pinnacle Associates Ltd. increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 34.9% during the 2nd quarter, Holdings Channel reports. The fund owned 161,020...\n more…

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Wealth Enhancement Advisory Services LLC
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Wealth Enhancement Advisory Services LLC

Ticker Report Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.3% in the 2nd quarter, according to the company in its most...\n more…

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...\n more…